Skip to main content
. Author manuscript; available in PMC: 2023 Jan 5.
Published in final edited form as: Clin Cancer Res. 2022 Aug 2;28(15):3356–3366. doi: 10.1158/1078-0432.CCR-21-2834

Figure 2.

Figure 2.

Standard-of-care first-line platinum-based chemotherapy increases T cell responses to viral antigens following chemotherapy. A, IFNγ ELISpot responses to influenza (FluA) and CEF peptide pools over the course of chemotherapy in patient 6 (CA125 complete responder). OKT CD3 (anti-CD3ε antibody) served as a positive control. B and C, IFNγ ELISpot responses to FluA and CEF peptide pools over the course of chemotherapy in CA125 complete responders (Pts. 1, 2, 4, and 6) (B) and CA125 incomplete responders (Pts. 7, 8, and 10) (C). Spot forming cell (SFC) per 106 PBMCs were background (OVA)-subtracted with n = 3 biologically independent samples. All data points represent mean ± standard error of the mean (s.e.m.). A repeated-measures regression model was used for generating P-values. *P ≤ 0.05.